Details of the Drug Combination

General Information of Drug Combination (ID: DCXZZLY)

Drug Combination Name

SGC707 Rotenone

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

SGC707 DMGINBT

Rotenone DMV04ES

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 43.77

Bliss Independence Score: 40.826

Loewe Additivity Score: 1.861

LHighest Single Agent (HSA) Score: 9.337

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of SGC707

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

SGC707 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protein arginine methyltransferase 3 (PRMT3)	TTL4XSQ	ANM3_HUMAN	Modulator (allosteric modulator)	[2]
------------------------------------------------------------------------------------

SGC707 Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Protein arginine N-methyltransferase 3 (PRMT3)	OTH2KILE	ANM3_HUMAN	Affects Folding	[2]
------------------------------------------------------------------------------------

Indication(s) of Rotenone

Disease Entry	ICD 11	Status	REF
Piscicide	N.A.	Approved	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015